Q-omics provides the consensus-scored CCDC200 profile across patient tissues and cancer cell-line models. CCDC200 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, CCDC200 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, CCDC200 RNA expression shows 19,219 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and KIRC as cancer lineages where CCDC200 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCDC200 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCDC200 survival associations across molecular data types. CCDC200 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCDC200 RNA expression–survival associations across cancer types. High CCDC200 expression shows unfavorable associations in UVM, LGG and COAD, but favorable associations in HNSC, UCS and UCEC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for CCDC200 RNA expression.
This table summarizes CCDC200 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CCDC200. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCDC200 shows lower tumor expression in KICH, UCEC, LUSC and THCA and higher tumor expression in KIRC and HNSC. The KIRC box plot shows higher CCDC200 RNA expression in tumor versus normal tissue (log2 FC = +0.610, t-test p < 0.001).
This table shows molecular features associated with CCDC200 in patient tissues and cancer cell lines. In patient samples, CCDC200 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
